# US 12,213,955 B2 · Compositions and methods for broad-spectrum antiviral therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,213,955 B2
- Document ID: US12213955B2
- Status: Granted
- Kind: B2
- Application number: 16/757,312
- Filed: 2018-10-16
- Published: 2020-10-29
- Granted: 2025-02-04
- Earliest claimed: 2017-10-18
- Assignees: Versitech Limited
- Applicants: Versitech Limited
- Inventors: Shuofeng Yuan; Fuk Woo Jasper Chan; Hin Chu; Johnson Yiu-Nam Lau; Kwok Yung Yuen
- Web page: https://patentgrep.com/patent/US12213955B2

## CPC

- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61P 31/12: Antivirals
- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

AM580 and structurally related compounds have been found to be useful in treating infection by a wide range of RNA and DNA viruses, and also in reducing associated inflammation. This activity is independent of RAR-α signaling, and is not a result of activation of the hosts innate immune response. Broad antiviral activity of AM580 and structurally related compounds is a due to modulation of lipogenesis so as to correct disregulation of this pathway in virus-infected cells, via inhibition of nSREPBP.

## Claims

### Claim 1

A method of treating a viral infection, comprising: administering to a subject in need thereof, an effective amount of a compound AM580, having the structure:
wherein the viral infection is caused by a virus selected from the group consisting of MERS-CoV, SARS-CoV, Zika virus, Influenza A virus, Human Adenovirus, and Enterovirus.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound is administered in combination with a pharmaceutically active compound.

### Claim 3 (depends on 2)

The method of claim 2, wherein the pharmaceutically active compound is selected from the group consisting of an anti-viral compound, an anti-inflammatory compound, an analgesic compound, an anti-emetic, and an antibiotic.

### Claim 4

A method of reducing an inflammatory response associated with a viral infection, comprising administering to a subject in need thereof, an effective amount of the compound AM580, having the structure:
wherein the viral infection is caused by a virus selected from the group consisting of MERS-CoV, SARS-CoV, Zika virus, Influenza A virus, Human Adenovirus, and Enterovirus.

### Claim 5 (depends on 4)

The method of claim 4, wherein the compound reduces interstitial inflammation or alveolar damage.

### Claim 6 (depends on 4)

The method of claim 4, wherein the compound reduces viral induced activation of a pro-inflammatory cytokine.

### Claim 7 (depends on 6)

The method of claim 6, wherein the pro-inflammatory cytokine is selected from the group consisting of TNFα, IL-1β, IL-6, and IL-8.

### Claim 8 (depends on 4)

The method of claim 4, wherein the compound is administered in combination with a pharmaceutically active compound.

### Claim 9 (depends on 1)

The method of claim 1, wherein the compound is administered in a pharmaceutically acceptable carrier.

### Claim 10 (depends on 4)

The method of claim 4, wherein the compound is administered in a pharmaceutically acceptable carrier.

### Claim 11 (depends on 1)

The method of claim 1, wherein the effective amount of the compound ranges from 1 μg/kg body weight of the subject to 100 mg/kg body weight of the subject.

### Claim 12 (depends on 1)

The method of claim 1, wherein the viral infection is caused by Influenza A (H1N1) pdm09, Influenza virus A (H5N1), or Influenza virus A (H7N9).

### Claim 13 (depends on 1)

The method of claim 1, wherein the viral infection is caused by Human Adenovirus 5.

### Claim 14 (depends on 1)

The method of claim 1, wherein the effective amount of the compound ranges from 5 μM to 100 μM.